Similar articles

• Pulse versus daily oral cyclophosphamide in ANCA-associated vasculitis.

  Hebert LA, Rovin BH. Hebert LA, et al. Ann Intern Med. 2010 Jan 5;152(1):64; author reply 65. doi: 10.7326/0003-4819-152-1-201001050-00020. Ann Intern Med. 2010. PMID: 20048278 No abstract available.
• Pulse versus daily oral cyclophosphamide in ANCA-associated vasculitis.

  Padhan P. Padhan P. Ann Intern Med. 2010 Jan 5;152(1):64; author reply 65. doi: 10.7326/0003-4819-152-1-201001050-00019. Ann Intern Med. 2010. PMID: 20048279 No abstract available.
• [Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis (CYCLOPS study)].

  Kötter I. Kötter I. Z Rheumatol. 2009 Sep;68(7):575-7. doi: 10.1007/s00393-009-0509-4. Z Rheumatol. 2009. PMID: 19652987 German. No abstract available.
• The CARI guidelines. Induction and maintenance therapy in ANCA-associated systemic vasculitis.

  Menahem S, Hiremagalur B, Mudge D, Toussaint N, Walters G; Caring for Australians with Renal Impairment (CARI). Menahem S, et al. Nephrology (Carlton). 2008 Jul;13 Suppl 2:S24-36. doi: 10.1111/j.1440-1797.2008.00995.x. Nephrology (Carlton). 2008. PMID: 18713121 Review. No abstract available.
• Adverse effects of therapy for ANCA-associated vasculitis.

  Turnbull J, Harper L. Turnbull J, et al. Best Pract Res Clin Rheumatol. 2009 Jun;23(3):391-401. doi: 10.1016/j.berh.2009.04.002. Best Pract Res Clin Rheumatol. 2009. PMID: 19508946 Review.